695 related articles for article (PubMed ID: 16393430)
41. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
Mori E; Ikeda M; Iseki E; Katayama S; Nagahama Y; Ohdake M; Takase T
Psychogeriatrics; 2024 May; 24(3):542-554. PubMed ID: 38439118
[TBL] [Abstract][Full Text] [Related]
42. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
43. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
44. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
45. [Medical treatment of Alzheimer's disease].
Johannsen P
Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
[TBL] [Abstract][Full Text] [Related]
46. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
47. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Bullock R; Connolly C
Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
[No Abstract] [Full Text] [Related]
48. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
49. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Scacchi R; Gambina G; Broggio E; Corbo RM
Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
[TBL] [Abstract][Full Text] [Related]
50. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
51. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
Bhasin M; Rowan E; Edwards K; McKeith I
Int J Geriatr Psychiatry; 2007 Sep; 22(9):890-5. PubMed ID: 17265415
[TBL] [Abstract][Full Text] [Related]
52. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Mauskopf JA; Paramore C; Lee WC; Snyder EH
J Manag Care Pharm; 2005 Apr; 11(3):231-51. PubMed ID: 15804207
[TBL] [Abstract][Full Text] [Related]
53. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial.
Jia J; Wei C; Jia L; Tang Y; Liang J; Zhou A; Li F; Shi L; Doody RS
J Alzheimers Dis; 2017; 56(4):1495-1504. PubMed ID: 28157100
[TBL] [Abstract][Full Text] [Related]
55. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
56. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Wattmo C; Wallin AK; Minthon L
BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
[TBL] [Abstract][Full Text] [Related]
57. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
59. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
Holmes C; Wilkinson D; Dean C; Vethanayagam S; Olivieri S; Langley A; Pandita-Gunawardena ND; Hogg F; Clare C; Damms J
Neurology; 2004 Jul; 63(2):214-9. PubMed ID: 15277611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]